Head and neck cancer is among the few solid tumors whose incidence is increasing in the U.S. and outcomes have been slow to improve. Results of a phase 1 trial of the drug CUCD-101 with radiation and chemotherapy were reported by the University of Colorado Cancer Center and 6 other U.S. cancer centers in the journal Clinical Cancer Research. CUDC-101, currently being developed by Curis, Inc., works by inhibiting two growth factors and an enzyme that effects DNA expression - EGFR, Her2 and HDAC - all of which are overexpressed in many cancers, including the target of this trial: the common type of especially aggressive head and neck cancer that is not caused by the human papilloma virus (HPV-) but rather by tobacco or alcohol.
"We pretty much threw the kitchen sink at it," says Antonio Jimeno, MD, PhD, the clinical trial's senior author and director of the University of Colorado School of Medicine's Head and Neck Cancer Clinical Research Program. In the phase 1 trial CUDC-101 was combined with the standard of care for treatment of head and neck cancer, which includes the chemotherapy drug cisplatin and radiation.
"Substantial technological advances in how we deliver radiation and chemotherapy are now enabling the addition of targeted agents to improve the cure rates and functional results in our patients," Jimeno says.
Specifically, the study was performed in 12 medium- to high-risk head and neck cancer patients. At 18 months median follow up, one patient's cancer had worsened, two had died, and nine remained free of disease. Testing of blood and tumor samples showed that CUDC-101 had indeed inhibited the action of EGFR, HDAC and Her2.
"By analyzing the molecular correlates obtained from our very motivated and generous patients we saw that the drug was doing what it was supposed to be doing. The fact that this complex trial was feasible and didn't significantly add to the toxicity of chemotherapy and radiation that was given along with the study drug makes everybody more excited about pursuing further trials," Jimeno says.
"This is one of the most complex studies undertaken by the Head and Neck Cancer program at the CU Cancer Center to date. We are proud to have led patient enrolment to complete the trial, which defined the proper dosing for this new drug. As much as the results, the trial mechanics themselves contributed to our ability to publish these findings in the leading journal for this kind of research with a trial of only 12 patients," Jimeno points out.
"Multidisciplinary care and access to clinical trials such as this one are probably among the factors that contribute to higher cure rates in dedicated, specialized Head and Neck Cancer Programs such as ours," Jimeno says.
Explore further: Discovery could lead to better head and neck cancer therapies
More information: Clinical Cancer Research, http://ift.tt/1JuvNiu
Medical Xpress on facebook
Related Stories
Rigosertib Phase 1 results lead to disease-focused Phase 2 development
Apr 09, 2013
Results of a phase 1 clinical trial reported at the American Association for Cancer Research (AACR) annual conference show that orally administered Rigosertib is well tolerated in patients with advanced solid tumors. This ...
Discovery could lead to better head and neck cancer therapies
Nov 10, 2014
UCLA scientists have discovered that a protein usually linked to rare neurological disorders is also associated with head and neck cancer in people who are infected with the human papilloma virus. And when that protein is ...
Experience counts with radiation therapy for head and neck cancer, study shows
Dec 08, 2014
When it comes to specialized cancer surgery, it's generally true that the more experienced the surgeon, the better the outcome. The same might hold true for radiation therapy used to treat head and neck cancer, according ...
Coupling head and neck cancer screening and lung cancer scans could improve survival
Jan 09, 2015
Adding head and neck cancer screenings to recommended lung cancer screenings would likely improve early detection and survival, according to a multidisciplinary team led by scientists affiliated with the University of Pittsburgh ...
Roche breast cancer drug 'helps patients live longer': study
Sep 29, 2014
A drug developed by Swiss giant Roche to treat an aggressive form of breast cancer has been shown to extend patients' lives by almost 16 months, researchers said Sunday.
Recommended for you
Study finds potential new drug target for lung cancer
2 hours ago
A new study by University of Kentucky Markey Cancer Center researchers suggests that targeting a key enzyme and its associated metabolic programming may lead to novel drug development to treat lung cancer.
An engineering approach from Virginia Tech helps breast cancer researchers at Georgetown
3 hours ago
Biologists working with engineers and physicists have found a molecule they say helps determine if breast cancer cells that are resistant to antiestrogen therapy will live or die.
Swedish model for PSA testing has little effect on mortality
3 hours ago
The spontaneous PSA testing that has been applied in Sweden in recent decades has only had a marginal effect on mortality. An organized screening focused on those who have the most to gain would, however, reduce the risk ...
How cancer turns good cells to the dark side
4 hours ago
Cancer uses a little-understood element of cell signaling to hijack the communication process and spread, according to Rice University researchers.
New exam nearly quadruples detection of invasive breast cancers in dense breast tissue
7 hours ago
A new breast imaging technique pioneered at Mayo Clinic nearly quadruples detection rates of invasive breast cancers in women with dense breast tissue, according to the results of a major study published this week in the ...
Many women with breast cancer have poor knowledge about their condition
14 hours ago
A new analysis has found that many women with breast cancer lack knowledge about their illness, with minority patients less likely than white patients to know and report accurate information about their tumors' characteristics. ...
User comments
Please sign in to add a comment. Registration is free, and takes less than a minute. Read more
Click here to reset your password.
Sign in to get notified via email when new comments are made.
© Medical Xpress 2011-2014, Science X network
Head and neck cancer is among the few solid tumors whose incidence is increasing in the U.S. and outcomes have been slow to improve. Results of a phase 1 trial of the drug CUCD-101 with radiation and chemotherapy were reported by the University of Colorado Cancer Center and 6 other U.S. cancer centers in the journal Clinical Cancer Research. CUDC-101, currently being developed by Curis, Inc., works by inhibiting two growth factors and an enzyme that effects DNA expression - EGFR, Her2 and HDAC - all of which are overexpressed in many cancers, including the target of this trial: the common type of especially aggressive head and neck cancer that is not caused by the human papilloma virus (HPV-) but rather by tobacco or alcohol.
"We pretty much threw the kitchen sink at it," says Antonio Jimeno, MD, PhD, the clinical trial's senior author and director of the University of Colorado School of Medicine's Head and Neck Cancer Clinical Research Program. In the phase 1 trial CUDC-101 was combined with the standard of care for treatment of head and neck cancer, which includes the chemotherapy drug cisplatin and radiation.
"Substantial technological advances in how we deliver radiation and chemotherapy are now enabling the addition of targeted agents to improve the cure rates and functional results in our patients," Jimeno says.
Specifically, the study was performed in 12 medium- to high-risk head and neck cancer patients. At 18 months median follow up, one patient's cancer had worsened, two had died, and nine remained free of disease. Testing of blood and tumor samples showed that CUDC-101 had indeed inhibited the action of EGFR, HDAC and Her2.
"By analyzing the molecular correlates obtained from our very motivated and generous patients we saw that the drug was doing what it was supposed to be doing. The fact that this complex trial was feasible and didn't significantly add to the toxicity of chemotherapy and radiation that was given along with the study drug makes everybody more excited about pursuing further trials," Jimeno says.
"This is one of the most complex studies undertaken by the Head and Neck Cancer program at the CU Cancer Center to date. We are proud to have led patient enrolment to complete the trial, which defined the proper dosing for this new drug. As much as the results, the trial mechanics themselves contributed to our ability to publish these findings in the leading journal for this kind of research with a trial of only 12 patients," Jimeno points out.
"Multidisciplinary care and access to clinical trials such as this one are probably among the factors that contribute to higher cure rates in dedicated, specialized Head and Neck Cancer Programs such as ours," Jimeno says.
Explore further: Discovery could lead to better head and neck cancer therapies
More information: Clinical Cancer Research, http://ift.tt/1JuvNiu
Medical Xpress on facebook
Related Stories
Rigosertib Phase 1 results lead to disease-focused Phase 2 development
Apr 09, 2013
Results of a phase 1 clinical trial reported at the American Association for Cancer Research (AACR) annual conference show that orally administered Rigosertib is well tolerated in patients with advanced solid tumors. This ...
Discovery could lead to better head and neck cancer therapies
Nov 10, 2014
UCLA scientists have discovered that a protein usually linked to rare neurological disorders is also associated with head and neck cancer in people who are infected with the human papilloma virus. And when that protein is ...
Experience counts with radiation therapy for head and neck cancer, study shows
Dec 08, 2014
When it comes to specialized cancer surgery, it's generally true that the more experienced the surgeon, the better the outcome. The same might hold true for radiation therapy used to treat head and neck cancer, according ...
Coupling head and neck cancer screening and lung cancer scans could improve survival
Jan 09, 2015
Adding head and neck cancer screenings to recommended lung cancer screenings would likely improve early detection and survival, according to a multidisciplinary team led by scientists affiliated with the University of Pittsburgh ...
Roche breast cancer drug 'helps patients live longer': study
Sep 29, 2014
A drug developed by Swiss giant Roche to treat an aggressive form of breast cancer has been shown to extend patients' lives by almost 16 months, researchers said Sunday.
Recommended for you
Study finds potential new drug target for lung cancer
2 hours ago
A new study by University of Kentucky Markey Cancer Center researchers suggests that targeting a key enzyme and its associated metabolic programming may lead to novel drug development to treat lung cancer.
An engineering approach from Virginia Tech helps breast cancer researchers at Georgetown
3 hours ago
Biologists working with engineers and physicists have found a molecule they say helps determine if breast cancer cells that are resistant to antiestrogen therapy will live or die.
Swedish model for PSA testing has little effect on mortality
3 hours ago
The spontaneous PSA testing that has been applied in Sweden in recent decades has only had a marginal effect on mortality. An organized screening focused on those who have the most to gain would, however, reduce the risk ...
How cancer turns good cells to the dark side
4 hours ago
Cancer uses a little-understood element of cell signaling to hijack the communication process and spread, according to Rice University researchers.
New exam nearly quadruples detection of invasive breast cancers in dense breast tissue
7 hours ago
A new breast imaging technique pioneered at Mayo Clinic nearly quadruples detection rates of invasive breast cancers in women with dense breast tissue, according to the results of a major study published this week in the ...
Many women with breast cancer have poor knowledge about their condition
14 hours ago
A new analysis has found that many women with breast cancer lack knowledge about their illness, with minority patients less likely than white patients to know and report accurate information about their tumors' characteristics. ...
User comments
Please sign in to add a comment. Registration is free, and takes less than a minute. Read more
Click here
to reset your password.
Sign in to get notified via email when new comments are made.
© Medical Xpress 2011-2014, Science X network
0 comments:
Post a Comment